Stocks · News reference

Polyrizon Publishes U.S. Patent Application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery"

Jun 17, 2026, 12:17 PMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jun 17, 2026, 12:17 PM
Checked: Jun 17, 2026, 12:20 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 20, 2026, 1:31 PMBenzinga Newsdesk
Polyrizon Completes Contracting With Fourth, Fifth Clinical Facilities Participating In Its Clinical Trial Of NASARIX Allergy Blocker
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed
Read original at benzinga
PLRZ
BenzingaJul 2, 2026, 8:13 PMBenzinga Newsdesk
Polyrizon Reports NASARIX Biocompatibility Results, Supporting Advancement To First-In-Human Clinical Trial
Read original at benzinga
PLRZ
BenzingaJun 29, 2026, 12:45 PMBenzinga Newsdesk
Polyrizon Receives Central IRB Approval To Begin First Human Clinical Trial For NASARIX, Nasal Spray Designed To Block Airborne Allergens
Read original at benzinga
PLRZ